Last reviewed · How we verify
ATG Thymoglobulin
T-cell depleting agent
T-cell depleting agent Used for Kidney transplantation, Bone marrow transplantation.
At a glance
| Generic name | ATG Thymoglobulin |
|---|---|
| Also known as | ATG Thymo, Antithymocyte globulin |
| Sponsor | St. Anna Kinderkrebsforschung |
| Drug class | Immunosuppressant |
| Target | CD3 receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Thymoglobulin is a polyclonal anti-human lymphocyte globulin that selectively depletes T-lymphocytes by binding to the CD3 receptor on the surface of T-cells, leading to their destruction.
Approved indications
- Kidney transplantation
- Bone marrow transplantation
Common side effects
- Thrombocytopenia
- Leukopenia
- Anemia
Key clinical trials
- A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation (PHASE2, PHASE3)
- Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis (PHASE4)
- Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients (PHASE2)
- A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes (PHASE1, PHASE2)
- Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders (PHASE2)
- Immune Tolerance Induction After Liver Transplantation (PHASE1, PHASE2)
- Allo HSCT for High Risk Hemoglobinopathies (PHASE2)
- Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |